Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback

Verve Therapeutics shares dropped more than 30% early Tuesday after the company paused enrollment in a trial of its gene-editing treatment for heart disease.

Previous post JPMorgan credit outlook upgraded to positive from stable at S&P for ‘superior resilience’
Next post How much will you need to retire? America’s ‘magic number’ surges to $1.46 million